Cargando…

Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer

BACKGROUND: Although most patients with metastatic castration-resistant prostate cancer (mCRPC) initially benefit from treatment with androgen receptor signaling inhibitors (ARSi), resistance inevitably occurs. Hence, we investigated the prognostic value of automated circulating tumor cell (CTC) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Oeyen, Steffi, Liégeois, Vincent, De Laere, Bram, Buys, Andy, Strijbos, Michiel, Dirix, Piet, Meijnders, Paul, Vermeulen, Peter, Van Laere, Steven, Dirix, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134056/
https://www.ncbi.nlm.nih.gov/pubmed/33230201
http://dx.doi.org/10.1038/s41391-020-00304-1
_version_ 1783695156981006336
author Oeyen, Steffi
Liégeois, Vincent
De Laere, Bram
Buys, Andy
Strijbos, Michiel
Dirix, Piet
Meijnders, Paul
Vermeulen, Peter
Van Laere, Steven
Dirix, Luc
author_facet Oeyen, Steffi
Liégeois, Vincent
De Laere, Bram
Buys, Andy
Strijbos, Michiel
Dirix, Piet
Meijnders, Paul
Vermeulen, Peter
Van Laere, Steven
Dirix, Luc
author_sort Oeyen, Steffi
collection PubMed
description BACKGROUND: Although most patients with metastatic castration-resistant prostate cancer (mCRPC) initially benefit from treatment with androgen receptor signaling inhibitors (ARSi), resistance inevitably occurs. Hence, we investigated the prognostic value of automated circulating tumor cell (CTC) and tumor-derived extracellular vesicle (tdEV) enumeration and their dynamics, in patients with mCRPC in the context of the initiation of treatment with ARSi. Furthermore, we hypothesize that CTC phenotypic heterogeneity might serve as a measurable biomarker under these circumstances. METHODS: Using an image analysis tool, we reanalyzed all CellSearch images previously acquired in the context of a prospective, multicenter clinical study for patients with mCRPC (n = 170) starting a new line of ARSi, for CTC and tdEV detection and enumeration. CTC (n = 19 129) phenotypic diversity was quantified by the Shannon index (SI). Progression-free survival (PFS) and overall survival (OS) were compared between groups of patients stratified according to CTC, tdEV, and SI levels. RESULTS: Automated CTC enumeration provided similar clinical prognostication compared with operator-based counts. Patients demonstrating high CTC phenotypic heterogeneity before therapy had a shorter median PFS (4.82 vs. 8.49 months, HR 1.79; P = 0.03) and OS (12.6 months vs. not reached, HR 2.32; P = 0.03), compared to patients with low diversity, irrespective of CTC level. Multivariable analysis showed how the prognostic value of the baseline SI was lost by pretreatment chemotherapy status, CTC counts, and PSA levels. CONCLUSIONS: Automated CTC counts are a reliable substitute for reviewer-based enumeration, as they are equally informative for prognosis assessment in patients with mCRPC. Beyond enumeration, we demonstrated the added value of studying CTC phenotypic diversity for patient prognostication, warranting future investigation.
format Online
Article
Text
id pubmed-8134056
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81340562021-06-01 Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer Oeyen, Steffi Liégeois, Vincent De Laere, Bram Buys, Andy Strijbos, Michiel Dirix, Piet Meijnders, Paul Vermeulen, Peter Van Laere, Steven Dirix, Luc Prostate Cancer Prostatic Dis Article BACKGROUND: Although most patients with metastatic castration-resistant prostate cancer (mCRPC) initially benefit from treatment with androgen receptor signaling inhibitors (ARSi), resistance inevitably occurs. Hence, we investigated the prognostic value of automated circulating tumor cell (CTC) and tumor-derived extracellular vesicle (tdEV) enumeration and their dynamics, in patients with mCRPC in the context of the initiation of treatment with ARSi. Furthermore, we hypothesize that CTC phenotypic heterogeneity might serve as a measurable biomarker under these circumstances. METHODS: Using an image analysis tool, we reanalyzed all CellSearch images previously acquired in the context of a prospective, multicenter clinical study for patients with mCRPC (n = 170) starting a new line of ARSi, for CTC and tdEV detection and enumeration. CTC (n = 19 129) phenotypic diversity was quantified by the Shannon index (SI). Progression-free survival (PFS) and overall survival (OS) were compared between groups of patients stratified according to CTC, tdEV, and SI levels. RESULTS: Automated CTC enumeration provided similar clinical prognostication compared with operator-based counts. Patients demonstrating high CTC phenotypic heterogeneity before therapy had a shorter median PFS (4.82 vs. 8.49 months, HR 1.79; P = 0.03) and OS (12.6 months vs. not reached, HR 2.32; P = 0.03), compared to patients with low diversity, irrespective of CTC level. Multivariable analysis showed how the prognostic value of the baseline SI was lost by pretreatment chemotherapy status, CTC counts, and PSA levels. CONCLUSIONS: Automated CTC counts are a reliable substitute for reviewer-based enumeration, as they are equally informative for prognosis assessment in patients with mCRPC. Beyond enumeration, we demonstrated the added value of studying CTC phenotypic diversity for patient prognostication, warranting future investigation. Nature Publishing Group UK 2020-11-23 2021 /pmc/articles/PMC8134056/ /pubmed/33230201 http://dx.doi.org/10.1038/s41391-020-00304-1 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Oeyen, Steffi
Liégeois, Vincent
De Laere, Bram
Buys, Andy
Strijbos, Michiel
Dirix, Piet
Meijnders, Paul
Vermeulen, Peter
Van Laere, Steven
Dirix, Luc
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
title Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
title_full Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
title_fullStr Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
title_full_unstemmed Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
title_short Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
title_sort automated enumeration and phenotypic characterization of ctcs and tdevs in patients with metastatic castration resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134056/
https://www.ncbi.nlm.nih.gov/pubmed/33230201
http://dx.doi.org/10.1038/s41391-020-00304-1
work_keys_str_mv AT oeyensteffi automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT liegeoisvincent automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT delaerebram automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT buysandy automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT strijbosmichiel automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT dirixpiet automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT meijnderspaul automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT vermeulenpeter automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT vanlaeresteven automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer
AT dirixluc automatedenumerationandphenotypiccharacterizationofctcsandtdevsinpatientswithmetastaticcastrationresistantprostatecancer